Jci_page_head_homepage_01 Jci_page_head_homepage_02
Yue Si, Chia-Lin Tsou, Kelsey Croft, Israel F. Charo
Published in Volume 120, Issue 4
J Clin Invest. 2010; 120(4):1192–1203 doi:10.1172/JCI40310
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 5
BM engraftment and long-term reconstitution of myeloid and lymphoid lineages with peritoneum-derived HSCs.

(A) Peritoneal Lin leukocytes from 12 thioglycollate-injected WT CD45.2 mice or Ccr2–/– mice were collected, mixed with 1 × 105 WT CD45.1 BM cells, and injected intravenously into lethally irradiated WT CD45.1 primary recipients. After 16 weeks, BM from the primary recipients was injected into lethally irradiated CD45.2 WT secondary recipients. (B) FACS plots show the percentage of CD45.2+ cells in the peripheral blood of the primary recipients at 8 and 16 weeks after transplantation and a secondary recipient at 16 weeks after transplantation. No engraftment was identified in mice injected with Ccr2–/–Lin peritoneal cells (data not shown). At 16 weeks, the mean percentage (±SD) of donor chimerism from primary and secondary recipients was 9 ± 3.6 and 2 ± 0.9. Shown are representative FACS plots. (C) Lineage analysis of donor CD45.2 cells in the blood of primary recipients 16 weeks after transplantation. Numbers in the upper right quadrant are percentages of CD45.2+ peripheral blood cells expressing the respective markers. Shown are representative FACS plots.